Agenus Inc. is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious disease. The Company's primary business is immuno-oncology, which is advancing antibody-based programs to activate innate and adaptive immunity, overcome tumor immune evasion and expand the population of patients from immunotherapy. Its lead clinical program is botensilimab, alone and in combination with balstilimab, is a clinical-stage immuno-oncology asset which may be used as standalone agents or be complimentary to botensilimab plus balstilimab. Its internal discovery and translation platforms support target identification, antibody generation, biomarker analysis, and candidate selection. The Company's clinical and preclinical portfolio include agents directed to CTLA-4, PD-1, CD137, CD73/TGF-beta, ILT2, LAG-3, TIM-3, and TIGIT, all of which remain as proprietary assets of Agenus.
Back to dashboard
Company Information
About this company
Key people
Garo H. Armen
Chairman of the Board, Chief Executive Officer, Co-Founder, Principal Financial Officer
Steven O'Day
Chief Medical Officer
Thomas L. Harrison
Lead Independent Director
Jennifer S. Buell
Director
Marco Tullio Marcucci
Director
Brian J. Corvese
Independent Director
Susan F. Hirsch
Independent Director
Click to see more
Key facts
- Shares in issue45.02m
- EPICAGEN
- ISINUS00847G8042
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$364.22m
- Employees81
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.